ArticleBioconjugate chemistry2026

Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer.

Idowu E Fadayomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.